The pharmaceutical subcontractor indicates an investment of 13.7 million euros. This envelope will be dedicated in particular to the transformation of the highly active tablet manufacturing area, allowing the factory to better respond to new regulations.
Increase production of oncological treatments
Delpharm Lille therefore aims to double its oncology production capacity and improve the competitiveness of the northern site which has nearly 400 employees. In 2023, its turnover amounted to 40 million euros. “Oncology products represent a minimal part of our turnover since they are currently around 4 to 5%.indicates Stéphane Lepeu, deputy general manager of Delpharm. Our ambition is to increase this proportion to 30% in the medium term.»
Indeed, the Lys-lez-Lannoy site is more focused on the manufacturing of medicinal substances such as hormones or even corticosteroids. In November 2024, the factory inaugurated a new packaging line making it possible to double the production rates of corticosteroids, going from 8 to 20 million boxes per year. This new line is part of a strategy to modernize the site, valued at 5.3 million euros supported by a subsidy from Bpifrance of 3.6 million euros. Worldwide, the group employs 6,500 people and achieves a turnover of 1.1 billion euros. It has eleven sites in France, two in Italy, two in Canada, two in the Netherlands and one in Poland.
Source: www.usinenouvelle.com
